Lactobacillus paracasei CBA l74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in Vitro and protective effects against colitis and an enteric pathogen in Vivo

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Zagato, Elena ^a   Mileti, Erika ^a   Massimiliano, Lucia ^b   Fasano, Francesca ^b   Budelli, Andrea ^b   Penna, Giuseppe ^a   Rescigno, Maria ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Abbott SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL MILK; CLINICAL EFFECTIVENESS; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; FERMENTATION; FERMENTED MILK; FERMENTED PRODUCT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS PARACASEI; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SUPERNATANT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; DENDRITIC CELLS; FERMENTATION; HUMANS; INFANT; INFANT FORMULA; INFLAMMATION MEDIATORS; LACTOBACILLUS; MICE; MICE, INBRED C57BL; MILK; PROTECTIVE AGENTS; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM;

EID: 84895753368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087615     Document Type: Article

References (40)

1. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biology 5: e177.
2. Madan JC, Farzan SF, Hibberd PL, Karagas MR (2012) Normal neonatal microbiome variation in relation to environmental factors, infection and allergy. Current opinion in pediatrics 24: 753-759.
3. Maynard CL, Elson CO, Hatton RD, Weaver CT (2012) Reciprocal interactions of the intestinal microbiota and immune system. Nature 489: 231-241.
4. Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336: 1268-1273.
5. Sim K, Powell E, Shaw AG, McClure Z, Bangham M, et al. (2013) The neonatal gastrointestinal microbiota: the foundation of future health? Archives of disease in childhood Fetal and neonatal edition 98: F362-364.
6. Cattaneo A, Burmaz T, Arendt M, Nilsson I, Mikiel-Kostyra K, et al. (2010) Protection, promotion and support of breast-feeding in Europe: progress from 2002 to 2007. Public health nutrition 13: 751-759.
7. Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, et al. (2009) Breastfeeding: A commentary by the ESPGHAN Committee on Nutrition. Journal of pediatric gastroenterology and nutrition 49: 112-125.
8. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, et al. (2000) Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. Journal of pediatric gastroenterology and nutrition 30: 61-67. (Pubitemid 30349947)
9. Howie PW, Forsyth JS, Ogston SA, Clark A, Florey CD (1990) Protective effect of breast feeding against infection. Bmj 300: 11-16. (Pubitemid 20022804)
10. Hasselbalch H, Jeppesen DL, Engelmann MD, Michaelsen KF, Nielsen MB (1996) Decreased thymus size in formula-fed infants compared with breastfed infants. Acta paediatrica 85: 1029-1032. (Pubitemid 26302759)
11. Koletzko B, Baker S, Cleghorn G, Neto UF, Gopalan S, et al. (2005) Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. Journal of pediatric gastroenterology and nutrition 41: 584-599. (Pubitemid 41579668)
12. Riva E, Verduci E, Agostoni C, Giovannini M (2005) Closer to the gold standard: an appraisal of formulae available in Italy for use in formula-fed infants. The Journal of international medical research 33: 595-611. (Pubitemid 43009587)
13. Agostoni C, Goulet O, Kolacek S, Koletzko B, Moreno L, et al. (2007) Fermented infant formulae without live bacteria. Journal of pediatric gastroenterology and nutrition 44: 392-397. (Pubitemid 46673395)
14. Mullie C, Yazourh A, Thibault H, Odou MF, Singer E, et al. (2004) Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatric research 56: 791-795. (Pubitemid 39403407)
15. Indrio F, Ladisa G, Mautone A, Montagna O (2007) Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatric research 62: 98-100. (Pubitemid 46985858)
16. Thibault H, Aubert-Jacquin C, Goulet O (2004) Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. Journal of pediatric gastroenterology and nutrition 39: 147-152.
17. Campeotto F, Suau A, Kapel N, Magne F, Viallon V, et al. (2011) A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. The British journal of nutrition: 1-10.
18. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M (2012) The impact of probiotics and prebiotics on the immune system. Nature reviews Immunology 12: 728-734.
19. Tsilingiri K, Rescigno M (2013) Postbiotics: what else? Beneficial microbes 4: 101-107.
20. Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, et al. (2012) Probiotic and postbiotic activity in health and disease: comparison on a novel polarised exvivo organ culture model. Gut.
21. Mileti E, Matteoli G, Iliev ID, Rescigno M (2009) Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4: e7056.
22. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, et al. (2005) Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. PNAS: In Press.
23. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, et al. (2007) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13: 236-243. (Pubitemid 46231326)
24. De Greef E, Vandenplas Y, Hauser B, Devreker T, Veereman-Wauters G (2013) Probiotics and IBD. Acta gastro-enterologica Belgica 76: 15-19.
25. Garai P, Gnanadhas DP, Chakravortty D (2012) Salmonella enterica serovars Typhimurium and Typhi as model organisms: revealing paradigm of hostpathogen interactions. Virulence 3: 377-388.
26. Menard S, Candalh C, Ben Ahmed M, Rakotobe S, Gaboriau-Routhiau V, et al. (2006) Stimulation of immunity without alteration of oral tolerance in mice fed with heat-treated fermented infant formula. Journal of pediatric gastroenterology and nutrition 43: 451-458. (Pubitemid 44569004)
27. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. (Pubitemid 41587888)
28. Pastorelli L, De Salvo C, Vecchi M, Pizarro TT (2013) The role of IL-33 in gut mucosal inflammation. Mediators of inflammation 2013: 608187.
29. Pushparaj PN, Li D, Komai-Koma M, Guabiraba R, Alexander J, et al. (2013) Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140: 70-77.
30. Sedhom MA, Pichery M, Murdoch JR, Foligne B, Ortega N, et al. (2012) Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut.
31. Duan L, Chen J, Zhang H, Yang H, Zhu P, et al. (2012) Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3 (+) regulatory Tcell responses in mice. Molecular medicine 18: 753-761.
32. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proceedings of the National Academy of Sciences of the United States of America 107: 18581-18586.
33. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, et al. (2000) Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105: 469-478. (Pubitemid 30127247)
34. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL (1996) Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. The Journal of clinical investigation 98: 2076-2085. (Pubitemid 26376296)
35. Van de Perre P (2003) Transfer of antibody via mother's milk. Vaccine 21: 3374-3376.
36. Cleary TG (2004) Human milk protective mechanisms. Advances in experimental medicine and biology 554: 145-154.
37. Ward TL, Hosid S, Ioshikhes I, Altosaar I (2013) Human milk metagenome: a functional capacity analysis. BMC microbiology 13: 116.
38. Segawa S, Fujiya M, Konishi H, Ueno N, Kobayashi N, et al. (2011) Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One 6: e23278.
39. Yan F, Cao H, Cover TL, Washington MK, Shi Y, et al. (2011) Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. The Journal of clinical investigation 121: 2242-2253.
40. Kato-Mori Y, Orihashi T, Kanai Y, Sato M, Sera K, et al. (2010) Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. Journal of medicinal food 13: 1460-1467.